|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,036 DKK | +0.49% |
|
+2.26% | -5.57% |
| 05-15 | Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation' | MT |
| 05-15 | Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% | MT |
Genmab A/S reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was DKK 4,143 million compared to DKK 2,834 million a year ago. Net income was DKK 1,325 million compared to DKK 210 million a year ago.
Basic earnings per share from continuing operations was DKK 20.29 compared to DKK 3.21 a year ago. Diluted earnings per share from continuing operations was DKK 20.18 compared to DKK 3.19 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -5.57% | 19.07B | |
| +8.29% | 114B | |
| +10.21% | 104B | |
| +0.20% | 22.28B | |
| -11.90% | 22.41B | |
| -37.36% | 18B | |
| -5.17% | 17.89B | |
| +7.70% | 14.28B | |
| +37.65% | 12.55B | |
| +271.25% | 7.62B |
GENMAB A/S 
